公开(公告)号：US20220119784A1

公开(公告)日：2022-04-21

申请号：US17311464

申请日：2019-12-09

Applicant: 2seventy bio, Inc.

Inventor： JORDAN JARJOUR ,  KYLE HAVENS ,  CONSTANTINE CHRYSOSTOMOU

IPC: C12N9/22

Abstract: The present disclosure provides homing endonuclease variants and megaTALs reprogrammed to bind and cleave a polynucleotide sequence in the genome. The homing endonuclease variants and megaTALs have been engineered to increase the thermostability and/or activity.

公开(公告)号：US20240336904A1

公开(公告)日：2024-10-10

申请号：US18258021

申请日：2021-12-16

Applicant: 2seventy bio, Inc.

Inventor： JORDAN JARJOUR ,  ANNE-RACHEL KROSTAG

IPC: C12N9/22 ,  A61K35/17 ,  C12N5/0783 ,  C12N15/10

CPC classification number: C12N9/22 ,  A61K35/17 ,  C12N5/0636 ,  C12N15/102 ,  C07K2319/81 ,  C12N2510/00 ,  C12Y301/11001 ,  C12Y301/11002

Abstract: The present disclosure provides improved genome editing compositions and methods for editing a double-strand DNA target site. The disclosure further provides genome edited cells produced by the compositions and methods described.

公开(公告)号：US20220324942A1

公开(公告)日：2022-10-13

申请号：US17608743

申请日：2020-05-07

Applicant: 2SEVENTY BIO, INC. ,  INHIBRX, INC.

Inventor： JORDAN JARJOUR ,  MARK POGSON ,  WAI-HANG LEUNG ,  KYLE JONES ,  WILLIAM CRAGO ,  ANGELICA SANABRIA ,  ANDREW HOLLANDS ,  JACOB GANO ,  MILTON MA ,  JOHN C. TIMMER ,  BRENDAN P. ECKELMAN

IPC: C07K14/705 ,  C07K14/73 ,  C07K14/725 ,  C07K16/28 ,  C12N9/90 ,  C07K14/715 ,  C07K14/005 ,  C12N15/86 ,  A61K35/17 ,  A61P35/00

Abstract: The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

公开(公告)号：US20220315638A1

公开(公告)日：2022-10-06

申请号：US17608739

申请日：2020-05-07

Applicant: 2SEVENTY BIO, INC. ,  INHIBRX, INC.

Inventor： JORDAN JARJOUR ,  MARK POGSON ,  WAI-HANG LEUNG ,  CHELSIE MACEDO ,  KYLE JONES ,  WILLIAM CRAGO ,  ANDREW HOLLANDS ,  MILTON MA ,  JOHN C. TIMMER ,  BRENDAN P. ECKELMAN

IPC: C07K14/725 ,  C07K16/28 ,  A61P35/00 ,  C12N5/0783 ,  A61K35/17

Abstract: The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

公开(公告)号：US20220177860A1

公开(公告)日：2022-06-09

申请号：US17311455

申请日：2019-12-09

Applicant: 2Seventy bio, Inc.

Inventor： JORDAN JARJOUR ,  KYLE HAVENS ,  JASDEEP MANN

IPC: C12N9/22 ,  C12N15/90 ,  A61K48/00 ,  A61K38/46 ,  C12N15/85

Abstract: The present disclosure provides improved homing endonuclease variants and megaTALs reprogrammed to bind and cleave the PDCD-1 gene.

公开(公告)号：US20240025963A1

公开(公告)日：2024-01-25

申请号：US17311776

申请日：2019-12-13

Applicant: 2seventy bio, Inc.

Inventor： JORDAN JARJOUR ,  WAI-HANG LEUNG

IPC: C07K14/73 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  A61P35/02

CPC classification number: C07K14/70514 ,  C07K14/70517 ,  C07K14/70578 ,  C07K14/71 ,  C07K16/2863 ,  A61P35/02 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/03 ,  C07K2319/20 ,  C07K2319/33

Abstract: The present disclosure provides improved compositions for adoptive T cell therapies targeting EGFR or EGRFvIII for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting EGFR or EGRFvIII and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

公开(公告)号：US20230031838A1

公开(公告)日：2023-02-02

申请号：US17764365

申请日：2020-09-30

Applicant: 2seventy bio, Inc.

Inventor： JORDAN JARJOUR ,  ALEXANDER ASTRAKHAN ,  WAI-HANG LEUNG

IPC: C12N9/90 ,  C07K14/725 ,  C07K14/73 ,  C07K14/705 ,  A61K35/17 ,  C07K16/28

Abstract: The present disclosure provides adoptive T cell therapies that have improved DARIC architectures for targeting tumor antigens and recruiting TCR signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

公开(公告)号：US20220323496A1

公开(公告)日：2022-10-13

申请号：US17608738

申请日：2020-05-07

Applicant: 2SEVENTY BIO, INC. ,  INHIBRX, INC.

Inventor： JORDAN JARJOUR ,  MARK POGSON ,  WAI-HANG LEUNG ,  LUCAS RASCON ,  ANGELICA SANABRIA ,  JOHN C. TIMMER ,  BRENDAN P. ECKELMAN

IPC: A61K35/17 ,  A61P35/00 ,  C07K14/73 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N15/62

Abstract: The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.